[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"overall-response-rate\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:overall-response-rate":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100599902","phase-2-bevacizumab-combined-with-cisplatin-versus-cisplatin-monotherapy-in-malignant-serous-effusions-100599902",false,"NCT07090525","Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions","Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions-A Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Voluntarily sign informed consent;\n2. Treatment naive serous effusion of patients with adenocarcinoma without activating gene mutation.\n3. Eastern Cooperative Oncology Group (ECOG) score ≤ 2;\n4. Survival is expected to exceed 3 months\n\nExclusion Criteria:\n\n* The subject had received anti-vascular endothelial growth factor (VEGF) small molecule tyrosine kinase inhibitors or monoclonal antibodies in the past 4 weeks; The subject had participated any clinical trials in the past 4 weeks; The subject had previously received bevacizumab of pleural perfusion therapy;\n\nLaboratory results:\n\nWhite blood cell count \\\u003C3 × 109 \u002F L, neutrophil count \\\u003C1.5 × 109 \u002F L, platelet \\\u003C75 × 109 \u002F L, or hemoglobin \\\u003C8g \u002F dL; Coagulation abnormalities (INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds or activated partial thromboplastin time (APTT) \\> 1.5 ULN), with bleeding tendency or being treated with thrombolysis or anticoagulation; Serum total bilirubin ≥1.5 ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 ULN in the absence of liver metastases; ALT or AST ≥5 ULN in liver metastases; Serum albumin \\\u003C30g \u002F L; Serum creatinine ≥ 1.5 ULN or creatinine clearance \\\u003C40ml \u002F min; Urine routine urinary protein ≥ ++, or 24 hours urine protein ≥ 1.0 g; Hypertension cannot be controlled by drugs; Heart disease with significant clinical symptoms, such as: congestive heart failure, coronary heart disease with symptom, arrhythmia hardly be controlled by drugs, myocardial infarction in 6 months, or heart failure; Imaging (CT or MRI) showed a tumor lesion 5 mm away from the large vessels, or the presence of invasive central vasculature of the central tumor; imaging (CT or MRI) showed significant cavitation or necrosis of the lung tumor; Other diseases that may cause haemoptysis; Imaging (CT or chest radiograph) showed significant pneumothorax, fluid pneumothorax; Bilateral pleural cavity to a large number of effusion or encapsulated pleural effusion; Obvious cough blood in 6 months, or daily hemoptysis amounted to half a teaspoon (2.5ml) or more; Significant bleeding symptoms or with definite bleeding tendency within 12 months before randomization, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, occult blood ++ and above, intracerebral hemorrhage, vasculitis, or with congenital or acquired coagulopathy disorders; Thrombosis, cancer thrombosis (including arteriovenous thrombosis, tumor thrombus, pulmonary embolism, transient ischemic attack, etc.) occurred within 12 months; There are gastrointestinal obstruction, peptic ulcer, Crohn's disease, ulcerative colitis and other gastrointestinal diseases or other diseases may cause gastrointestinal bleeding or perforation; Severe respiratory diseases, or need long-term oxygen, corticosteroid treatment of diseases such as chronic obstructive pulmonary disease, interstitial lung disease and respiratory failure; The toxicity of previous antineoplastic therapies has not yet recovered to below grade 2 or has not fully recovered; Patients with uncontrolled central nervous system metastasis; There are serious uncontrolled systemic diseases, such as nephrotic syndrome, infection, poorly controlled diabetes; Patients with active HIV（human immunodeficiency virus）, HBV（hepatitis B virus）, or HCV（hepatitis C virus） infection; Patients had undergone surgery (\\\u003C28 days) or did not heal completely, or had other unhealed wounds before the study; Patients known to be allergic to bevacizumab or any of the components of the drug; Pregnant or lactating female patients, or unwilling to take contraceptive measures of reproductive age patients (including men); There is a serious psychological or mental abnormality, or lack of compliance; The investigator determines other circumstances that may affect the conduct of clinical studies and the determination of findings.","ALL",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The purpose of this study is to explore the efficacy and safety ofof bevacizumab plus cisplatin compare with cisplatin in the treatment of malignant serous effusion in patients with advanced adenocarcinoma",[25],"Overall Response Rate",[27,28,29],"Bevacizumab","malignant serous effusions","Randomized study","RECRUITING","2025-07-21",{"date":33,"type":34},"2025-07-29","ACTUAL",{"date":36,"type":34},"2025-07-01",{"date":38,"type":19},"2027-05-01",{"name":40,"class":41},"Qingdao Central Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100556943","precision-radiotherapy-for-tumours-using-magnetic-resonance-guided-linear-accelerator-mr-linac-100556943","NCT06531681","Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)","The Second Affiliated Hospital of Hainan Medical University","Inclusion Criteria:\n\n* Patients are undergoing or have undergone imaging or treatment at the MR linac;\n* Age 18-75 years, male or female;\n* ECOG score 0-2, life expectancy \\> 6 months;\n* Patients provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI;\n* The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy;\n* Acute inflammatory disease requiring systemic therapy;\n* The presence of active infectious disease;\n* Pregnant women, nursing mothers, and patients planning to have children during the study period.","18 Years","75 Years",{"count":53,"type":19},3000,"OBSERVATIONAL","Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.",[25,57,58,59],"Oncology","Radiation Toxicity","Quality of Life","2025-02-11",{"date":62,"type":34},"2025-02-13",{"date":64,"type":34},"2023-08-19",{"date":66,"type":19},"2028-12-31",{"name":48,"class":41},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":74,"targetDuration":4,"studyType":20,"phases":76,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":42},"100537376","a-study-on-the-safety-and-efficacy-of-the-combination-of-candenizumab-lenvatinib-and-sox-regimen-in-the-treatment-of-her2-negative-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-patients-100537376","NCT06277024","A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients","Inclusion Criteria:\n\n* Age: 18 years ≤ Age ≤ 75 years;\n* Locally advanced or metastatic HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histopathology or cytology that cannot be resected;\n* Has not received radiotherapy, chemotherapy, targeted therapy, or immunotherapy as the primary treatment option for advanced or metastatic diseases in the past; Participants with gastric or gastroesophageal junction adenocarcinoma who have previously received adjuvant or neoadjuvant chemotherapy, radiotherapy, and\u002For radiochemotherapy are eligible for enrollment as long as the last administration of the previous protocol occurred at least 6 months prior to randomization.\n* At least one measurable lesion #see Appendix 2#;\n* ECOG PS: 0-1 points #see Appendix 4#;\n* Estimated survival time\\>3 months;\n* The main organ function is normal and meets the following criteria:\n* Blood routine examination must meet the following criteria#no blood transfusion within 14 days#\n\n  1. HB ≥ 100g\u002FL,\n  2. WBC ≥ 3 × 109\u002FL\n  3. ANC ≥ 1.5 × 109\u002FL,\n  4. PLT ≥ 100 × 109\u002FL;\n* Biochemical examination must meet the following standards:\n\n  1. BIL\\\u003C1.5 times the upper limit of normal value #ULN#,\n  2. ALT and AST\\\u003C2.5ULN, GPT ≤ 1.5 × ULN;\n  3. Serum Cr ≤ 1ULN, endogenous creatinine clearance rate\\>60ml\u002Fmin #Cockcroft Gault formula#\n* Women of childbearing age must undergo a pregnancy test #serum# within 7 days before enrollment, and the result is negative. They are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug; For males, surgical sterilization or agreement to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug should be considered; 9# Not participating in other clinical studies before and during treatment; 10# The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.\n\nExclusion Criteria:\n\n* If a subject meets any of the following conditions, they will not be allowed to enter this study\n\n  * Patients with allergies or suspected allergies to research drugs or similar drugs;\n  * Suffering from other malignant tumors within the past 5 years, excluding skin basal cell or squamous cell carcinoma after radical surgery, or cervical carcinoma in situ;\n  * Received live vaccine within 4 weeks prior to enrollment or possibly during the study period;\n  * Suffering from active autoimmune diseases or having a history of autoimmune diseases within 4 weeks prior to enrollment;\n  * Previously received allogeneic bone marrow transplantation or organ transplantation;\n  * The patient currently has any disease or condition that affects drug absorption, or the patient is unable to take medication orally;\n  * The patient currently has hypertension that cannot be controlled by medication, which is defined as: patients with hypertension who cannot be well controlled with a single antihypertensive drug treatment #systolic blood pressure ≥ 150 mmHg, diastolic blood pressure ≥ 100mmHg#; Or use two or more antihypertensive drugs to control blood pressure in patients;\n  * Urinary routine indicates that urine protein is ≥ 2+, and the 24-hour urine protein volume is\\>1.0g;\n  * The patient currently has digestive tract diseases such as active gastric and duodenal ulcers, ulcerative colitis, or active bleeding from unresectable tumors, or other conditions determined by the researcher that may cause gastrointestinal bleeding or perforation;\n  * Patients with significant evidence of bleeding tendency or medical history within the 3 months prior to enrollment #bleeding\\>30 mL within 3 months, vomiting blood, black stool, and rectal bleeding#, hemoptysis #fresh blood\\>5 mL within 4 weeks#, or thromboembolic events #including stroke events and\u002For transient ischemic attacks# within 12 months;\n  * Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe\u002Funstable angina, or coronary artery bypass grafting surgery within 6 months prior to enrollment; Congestive heart failure is classified by the New York Heart Association #NYHA# as\\>level 2; Ventricular arrhythmia requiring medication treatment; Electrocardiogram #ECG# shows a QT interval of ≥ 480 milliseconds;\n  * Active or uncontrolled severe infection #≥ CTCAE level 2 infection#;\n  * Known human immunodeficiency virus #HIV# infection; Known clinically significant history of liver disease, including viral hepatitis \\[known carriers of hepatitis B virus #HBV# must exclude active HBV infection, i.e. HBV DNA positivity #\\>1 × 104 copies\u002FmL or\\>2000 IU\u002Fml#; Known hepatitis C virus infection #HCV# and HCV RNA positivity #\\>1 × 103 copies\u002FmL, or other types of hepatitis or cirrhosis;\n  * According to the judgment of the researchers, patients deemed unsuitable for inclusion in this study.",{"count":75,"type":19},50,[77],"NA","Evaluate the objective response rate (ORR) of the combination of candenizumab, lenvatinib, and SOX regimen for the treatment of HER2 negative advanced gastric or gastroesophageal junction adenocarcinoma patients",[25],[81],"gastric cancer","2024-02-17",{"date":84,"type":34},"2024-02-26",{"date":86,"type":34},"2023-01-01",{"date":88,"type":19},"2027-12-31",{"name":90,"class":41},"Fujian Medical University"]